2016 News Releases

Webcast ImageWebcast
Clearside Biomedical Inc at the Deutsche Bank 42nd Annual Health Care Conference  (Live)
05/03/17 at 4:10 p.m. ET
Clearside Biomedical Inc at the Deutsche Bank 42nd Annual Health Care Conference
Wednesday, May 3, 2017 4:10 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/14/16Clearside Biomedical, Inc. Added to NASDAQ Biotechnology Index
ALPHARETTA, Ga., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that it has been selected by NASDAQ for inclusion in the NASDAQ Biotechnology Index® (NBI). The annual re-ranking of the NBI will become effective at market open on Monday, December 19, 2016. The NBI is designed to track the performance of a set of NASDAQ-listed securiti... 
Printer Friendly Version
12/09/16Clearside Biomedical, Inc. Announces Pricing of Public Offering of Common Stock
ALPHARETTA, Ga., Dec. 09, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $9.00 per share. The gross proceeds from the offering to Clearside are expected to be $36.0 million.  All of the shares in the offering will be sold by Clear... 
Printer Friendly Version
12/07/16Clearside Biomedical, Inc. Announces Proposed Offering of Common Stock
ALPHARETTA, Ga., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock. All of the shares in the offering will be sold by Clearside. In addition, Clearside expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 m... 
Printer Friendly Version
11/15/16Clearside Biomedical, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Zuprata™ in Diabetic Macular Edema
ALPHARETTA, Ga., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the enrollment of the first patient in a Phase 1/2 clinical trial (the “HULK” trial) of Zuprata™, its proprietary suspension formulation of the corticosteroid triamcinolone acetonide, for the treatment of diabetic macular edema (“DME”). The HULK trial is an open-label, m... 
Printer Friendly Version
11/09/16Clearside Biomedical, Inc. Announces Third Quarter 2016 Financial Results and Provides Corporate Update
Phase 3 Program of Zuprata™ for Macular Edema Associated with Retinal Vein Occlusion to be Initiated in the First Half of 2017 Phase 1/2 Trial for Diabetic Macular Edema to be Initiated by the End of 2016 ALPHARETTA, Ga., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today reported financial results for the quarter ended September 30, 2016 and provi... 
Printer Friendly Version
11/08/16Clearside Biomedical, Inc. to Present at the 2016 Stifel Healthcare Conference on Wednesday, November 16, 2016
ALPHARETTA, Ga., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, announced that Daniel H. White, Chief Executive Officer and President of Clearside, will present at the 2016 Stifel Healthcare Conference on Wednesday, November 16, 2016 at 3:00pm EST at the Lotte New York Palace in New York, NY. The presentation will be webcast live and may ... 
Printer Friendly Version
11/08/16Clearside Biomedical, Inc. Names Rick McElheny as Vice President, Business Development
ALPHARETTA, Ga., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that Rick McElheny has been named Vice President, Business Development. Mr. McElheny is a highly accomplished executive with expertise in business development, finance, market research, strategic planning, and supply chain management within the specialty pha... 
Printer Friendly Version
11/02/16Clearside Biomedical, Inc. to Report Third Quarter 2016 Financial Results and Host Conference Call on Wednesday, November 9, 2016
ALPHARETTA, Ga., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, announced today that its third quarter 2016 financial results will be released at 7:00 a.m. on Wednesday, November 9, 2016. Following the release, Clearside will host a live conference call and webcast at 8:30 a.m. EST to discuss the Company’s financial results and provide a g... 
Printer Friendly Version
10/10/16Clearside Biomedical, Inc. to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting
Phase 2 Results in the Treatment of Macular Edema Associated with Retinal Vein Occlusion Phase 2 and Phase 1/2 Results in the Treatment of Macular Edema Associated with Non-Infectious Uveitis ALPHARETTA, Ga., Oct. 10, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that results from two clinical trials, including the TANZANITE tria... 
Printer Friendly Version
09/20/16Clearside Biomedical, Inc. to Present at the 2016 Ladenburg Thalmann Healthcare Conference
ALPHARETTA, Ga., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that Daniel H. White, Chief Executive Officer and President, will present at the 2016 Ladenburg Thalmann Healthcare Conference on Tuesday, September 27, 2016, at 10:30 a.m. EDT in at the Sofitel Hotel in New York, NY. Mr. White will provide a Clearside overvie... 
Printer Friendly Version
08/11/16Clearside Biomedical, Inc. Reports Second Quarter 2016 Financial Results
ALPHARETTA, Ga., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today reported a corporate update and financial results for the quarter ended June 30, 2016. “Completing our IPO in June provided the financial resources to continue our clinical efforts in administering drug therapies through the suprachoroidal space for the treatment of p... 
Printer Friendly Version
08/10/16Clearside Biomedical, Inc. to Present at the 2016 Wedbush PacGrow Healthcare Conference
ALPHARETTA, Ga., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that Daniel H. White, Chief Executive Officer and President, will present at the 2016 Wedbush PacGrow Healthcare Conference on Wednesday, August 17, 2016, at 12:45 p.m. EDT in New York, NY. Mr. White will provide a Clearside overview and business update. The p... 
Printer Friendly Version
08/04/16Clearside Biomedical, Inc. to Report Second Quarter 2016 Financial Results
ALPHARETTA, Ga., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, will provide a corporate update and report financial results for the second quarter ended June 30, 2016 before the NASDAQ market opens on Thursday, August 11, 2016. The company will not be conducting a conference call in conjunction with this earnings release. About Clears... 
Printer Friendly Version
08/03/16Clearside Biomedical, Inc. to Present Data from Phase 2 (DOGWOOD) Clinical Trial for the Treatment of Macular Edema Associated with Non-Infectious Uveitis at the 2016 ASRS Annual Meeting
ALPHARETTA, Ga., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that results from their Phase 2 clinical trial (DOGWOOD) and Phase 1/2 clinical trial for the treatment of macular edema associated with non-infectious uveitis will be presented at the 2016 Annual Meeting of the American Society of Retina Specialists (ASRS), Au... 
Printer Friendly Version
08/01/16Clearside Biomedical, Inc. Announces Promotion of Glenn Noronha, Ph.D. to Chief Scientific Officer and Jennifer M. Kissner, Ph.D. to Vice President, Clinical Development
ALPHARETTA, Ga., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that Glenn Noronha, Ph.D., has been promoted to Chief Scientific Officer and Jennifer M. Kissner, Ph.D., has been promoted to Vice President, Clinical Development. Both Drs. Noronha and Kissner will assume their roles immediately and will report to Daniel H. Wh... 
Printer Friendly Version
07/26/16Clearside Biomedical, Inc. Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion
78% of Patients Required No Additional Treatment in the Trial Arm with Concomitant Suprachoroidally Administered Zuprata™ and Intravitreally Administered Eylea® Patients Reached an Average BCVA Improvement of 19 Letters Over a 3-Month Period ALPHARETTA, Ga., July 26, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today reports additional top-line... 
Printer Friendly Version
06/01/16Clearside Biomedical, Inc. Announces Pricing of Initial Public Offering
ALPHARETTA, Ga., June 01, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the pricing of its initial public offering of 7,200,000 shares of its common stock at a public offering price of $7.00 per share.  In addition, Clearside has granted the underwriters a 30-day option to purchase up to an additional 1,080,000 shares of common sto... 
Printer Friendly Version
04/26/16Clearside Biomedical, Inc. Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion
Patients receiving a single treatment of ZUPRATA™ together with EYLEA® qualified for 60% fewer additional EYLEA retreatments over a 3-month period (p=0.013)Patients in the ZUPRATA + EYLEA arm achieved 19 letters of improvement in Best Corrected Visual Acuity as compared to 11 letters of improvement following EYLEA aloneALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc. today announced that its Phase 2 clinical trial evaluating concomitant administration of suprachoroidal ZUPRATA™, Clea... 
Printer Friendly Version
02/29/16Clearside Biomedical, Inc. Announces Appointment of Richard J. Croarkin to the Board of Directors
Alpharetta, GA (February 29, 2016) - Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced that Richard J. Croarkin has been appointed to Clearside's Board of Directors.  Mr. Croarkin is the former Senior Vice President of Finance, Chief Financial Officer & Corporate Strategy Officer of Alcon, Inc., and brings extensive global financial experience from working... 
Printer Friendly Version
01/08/16Clearside Biomedical, Inc. Files Registration Statement for Proposed Initial Public Offering
Alpharetta, GA (January 8, 2016) – Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission related to Clearside’s proposed initial public offering of shares of its common stock.  The number of shares to be offered and the price range for the proposed o... 
Printer Friendly Version
01/05/16Clearside Biomedical, Inc. Announces Positive Topline Data from Phase 2 Clinical Trial for the Treatment of Macular Edema Associated with Non-Infectious Uveitis
Clinical Trial Achieves Statistical Significance on Primary Efficacy Endpoint   Alpharetta, GA (January 5, 2016) - Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced positive results from the company’s Phase 2 clinical trial of CLS-TA, Clearside’s proprietary form of triamcinolone acetonide, using suprachoroidal space (SCS™) drug administration for the treatm... 
Printer Friendly Version